The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice.

Lincoln D Nadauld, Charles H McDonnell, Tomasz M Beer, Minetta C Liu, Eric A Klein, Andrew Hudnut, Richard A Whittington, Bruce Taylor, Geoffrey R Oxnard, Jafi Lipson, Margarita Lopatin, Rita Shaknovich, Karen C Chung, Eric T Fung, Deborah Schrag

July 2021 Cancers (Basel)

Synopsis of Social media discussions

The discussions reflect a keen interest in the study's potential, highlighted by phrases like 'aimed at how MCED integrates in standards of care' and references to detailed data such as 'PPV 44.6%' and participant risks. The tone shows cautious optimism, balancing enthusiasm with acknowledgment of the ongoing nature of research, which explains the moderate scores across engagement and impact.

A
Agreement
 Moderate agreement

Most discussions acknowledge the significance of the PATHFINDER study and its potential for early cancer detection, though some remain cautiously optimistic rather than fully endorsing it.

I
Interest
 High level of interest

The social discussions demonstrate high interest, referencing detailed aspects of the study like signal percentages, prevalence, and integration into clinical practice.

E
Engagement
 Moderate level of engagement

Participants reference specific details such as the study's methodology, participant risk factors, and ongoing related research, indicating moderate depth of engagement.

I
Impact
 Moderate level of impact

Discussions suggest recognition of potential transformative effects on screening and diagnosis but also highlight that results are preliminary and part of ongoing research, implying moderate perceived impact.

Social Mentions

YouTube

2 Videos

Twitter

5 Posts

News

8 Articles

Metrics

Video Views

17

Total Likes

6

Extended Reach

13,105

Social Features

15

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Advancements in Multicancer Early Detection Blood Test

Advancements in Multicancer Early Detection Blood Test

This video explores a multicancer early detection test using methylation-based sequencing of cell-free DNA in blood, aiming to improve early cancer diagnosis and integration into clinical practice.

ReachMD

April 8, 2024

9 views

Implementing Multicancer Early Detection in Clinical Practice

Implementing Multicancer Early Detection in Clinical Practice

The PATHFINDER study evaluates a new blood test based on methylated cell-free DNA for early detection of multiple cancers in individuals aged 50 and above. This clinical trial assesses test accuracy, follow-up diagnostics, and integration into current medical procedures to improve early cancer detection.

ReachMD

April 8, 2024

8 views

  • the paper link
    @the_paper_link (Twitter)

    https://t.co/4thOXpm25p #prime2 Nadauld LD, ..., Marinac CR (Cancers (Basel)) __The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice__ https://t.co/8lzquB0LNq
    view full post

    May 1, 2023

  • Dale Yuzuki
    @DaleYuzuki (Twitter)

    Wood #AACR23 Grail's Pathfinder study. 6200 participants, 15 institutions. Age >50, history of cancer or smoking, another group average risk. 2021 ref https://t.co/ljSzGdpM6o Overall signal 1.4%; high risk 1.5%. PPV 44.6%, 57.1% in high risk. Most with Dx resolution 57/63
    view full post

    April 18, 2023

    1

  • Dr Sam Merriel
    @SamMerriel (Twitter)

    @Dr_PJEdwards @CanTest_PC @CRUKresearch @CaPRINetwork @BoomboomchiefsT @richarddneal @fmw22 @GLyratzopoulos @BrianDNicholson @drtomround @FunstonGarth Hi @Dr_PJEdwards Some papers https://t.co/gb72oClQGT https://t.co/WVY7zEvHJC Try these sites https://t.co/xhmSdcaZBD https://t.co/vl6CPWVc41
    view full post

    September 13, 2021

    1

  • Raymond McCauley
    @raymondmccauley (Twitter)

    @sbarnettARK The PATHFINDER study, of the GRAIL cfDNA + methylation, will roll-up the results of STRIVE (BrCa screen) & SUMMIT (high risk lung), both ongoing. So not yet demo'd. But aimed at how MCED integrates in standards of care. https://t.co/4JWAVistL4
    view full post

    August 18, 2021

    2

  • Paperbirds_Oncology
    @PaperbirdsO (Twitter)

    New article: The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice https://t.co/pASGYQmj0W #kidneycancer #oncology https://t.co/JnRJGEFmrz
    view full post

    July 24, 2021

Abstract Synopsis

  • The PATHFINDER study is a large, ongoing clinical trial that evaluates a new blood test (based on detecting methylated cell-free DNA) for early detection of multiple cancers in people aged 50 and above, with some additional risk factors.
  • The main goal is to determine how many follow-up diagnostic tests are needed after a positive cancer signal is detected and how accurately the test identifies cancer, with the expectation of diagnosing about 52 cancers among the participants.
  • This study aims to see how well this blood test can be integrated into current medical practice and improve early cancer detection by analyzing test performance, diagnostic pathways, and predictive value.]